There is no genuine analyst consensus for CYPH. Only one current, credible published target exists: Cantor Fitzgerald's Nathan Frankovitz initiated coverage with an Overweight rating and a $0.90 target on July 1, 2026, raised it to $1.60 in August, and lifted it again to $4.90 on September 10, 2026. The firm argued Zcash offers a technically advanced base-layer privacy model enabling "shielded" transactions, positioning CYPH to become the primary regulated public-market vehicle for institutional Zcash exposure. Because this is a single analyst's figure rather than an average of multiple targets, it should be read as one firm's view, not a consensus forecast. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry. Earlier coverage from HC Wainwright and Baird dated to early 2025 and is now stale.
CYPH closed near $1.87 on November 13, 2026, within a 52-week range of roughly $0.49 to $4.19. Reaching $4.90 would require a gain of about 160% from current levels, a very large move. The company generates little conventional revenue; trailing earnings reflect fair-value changes on its Zcash holdings rather than operating profit. A path toward the target would likely require a sustained advance in Zcash, continued institutional interest in privacy-oriented digital assets, and the company preserving its treasury while managing heavy share issuance.
The 52-week high near $4.19 is the nearest significant prior peak below the $4.90 target, while the 200-day moving average near $1.35 has acted as longer-term support. The stock's 50-day average sits near $2.87, above the current price, indicating recent weakness within a longer-term recovery. With an RSI (relative strength index) near 39, momentum has cooled from recent highs. Short interest at roughly 13.7% of shares outstanding is a structural factor that can magnify moves. From what I see, monitoring these levels closely helps frame the risk-reward profile.
The $4.90 target carries a standard 12-month research horizon, though it is one firm's view rather than a defined timeline. Investors should monitor Zcash's price, the company's quarterly reports and any disclosure around its ZEC holdings, further equity offerings and dilution, changes in short interest, and any additional analyst initiations or target revisions. Regulatory developments affecting digital asset custody and privacy coins would also be relevant. In my view, this is important because the setup leaves room for outsized moves in either direction.
Tickeron's AI Daily Buy/Sell Signals have become a useful part of my routine for names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For low-coverage, volatile stocks such as CYPH, it helps surface momentum changes without relying solely on manual review. I find it particularly practical when tracking crypto-tied equities where price action can shift quickly.
The $4.90 target for CYPH is a single analyst's price target, not a consensus, and reaching it would require a very large gain of roughly 160% from current levels. The bull case leans on Zcash exposure and the company's unique position as a regulated crypto treasury vehicle, while dilution, cash constraints, and crypto volatility are the principal obstacles. With only one active analyst and elevated short interest, the stock is prone to outsized swings in either direction. Investors should treat the target as one firm's scenario and watch Zcash prices, share issuance, and any new analyst coverage as the key signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CYPH moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend. In 45 of 50 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYPH as a result. In 64 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CYPH turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
The 10-day moving average for CYPH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CYPH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +21.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYPH advanced for three days, in 216 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CYPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.228) is normal, around the industry mean (2.423). P/E Ratio (4.500) is within average values for comparable stocks, (8.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.318). Dividend Yield (0.000) settles around the average of (0.274) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (15.906).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in clinical stage immuno-oncology
Industry InvestmentManagers